Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2004 Sep 15:4:13.
doi: 10.1186/1472-6882-4-13.

Harpgophytum procumbens for osteoarthritis and low back pain: a systematic review

Joel J Gagnier  1 , Sigrun Chrubasik, Eric Manheimer
Affiliations
Comparative Study

Harpgophytum procumbens for osteoarthritis and low back pain: a systematic review

Joel J Gagnier et al. BMC Complement Altern Med. .

Abstract

Background: The objective of this review is to determine the effectiveness of Harpagophytum procumbens preparations in the treatment of various forms of musculoskeletal pain.

Methods: Several databases and other sources were searched to identify randomized controlled trials, quasi-randomized controlled trials, and controlled clinical trials testing Harpagophytum preparations in adults suffering from pain due to osteoarthritis or low back pain.

Results: Given the clinical heterogeneity and insufficient data for statistical pooling, trials were described in a narrative way, taking into consideration methodological quality scores. Twelve trials were included with six investigating osteoarthritis (two were identical trials), four low back pain, and three mixed-pain conditions.

Conclusions: There is limited evidence for an ethanolic Harpagophytum extract containing less than <30 mg harpagoside per day in the treatment of knee and hip osteoarthritis. There is moderate evidence of effectiveness for (1) the use of a Harpagophytum powder at 60 mg harpagoside in the treatment of osteoarthritis of the spine, hip and knee; (2) the use of an aqueous Harpagophytum extract at a daily dose of 100 mg harpagoside in the treatment of acute exacerbations of chronic non-specific low back pain; and (3) the use of an aqueous extract of Harpagophytum procumbens at 60 mg harpagoside being non-inferior to 12.5 mg rofecoxib per day for chronic non-specific low-back pain (NSLBP) in the short term. Strong evidence exists for the use of an aqueous Harpagophytum extract at a daily dose equivalent of 50 mg harpagoside in the treatment of acute exacerbations of chronic NSLBP.

PubMed Disclaimer

References

    1. ESCOP Monograph. Harpagophyti radix, Fascicule 2. 1996. http://www.escop.com/ ISBN 1-901964-01-9.
    1. Lanhers MC, Fleurentin J, Mortier F, Vinche A, Younos C. Antiinflammatory and analgesic effects of an aquous extract of Harpagophytum procumbens. Planta Medica. 1992;58:117–123. - PubMed
    1. Chrubasik S, Wink N. Zur pharmakologischen Wirkung der Teufelskralle(Harpagophytum procumbens) Forschende Komplementärmedizin. 1995;2:323–325.
    1. Fiebich BL, Heinrich M, Hiller K-O, Kammerer N. Inhibition of TNFformula image synthesis in LPS-stimulated primary human monocytes by Harpagophytum extract SteiHap 69. Phytomedicine. 2001;8:28–30. - PubMed
    1. Chrubasik S, Fiebich B, Black A, Pollak S. Treating low back pain with an extract of Harpagophytum that inhibits cytokine release. Eur J Anaesthesiol. 2002;19:209.